CB2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene
- 1 January 2014
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 443 (1) , 144-149
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (ES11564, EY13632, DA11551)
This publication has 23 references indexed in Scilit:
- The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical PracticeCurrent Clinical Pharmacology, 2013
- Selective cannabinoid receptor 2 modulators: a patent review 2009 – presentExpert Opinion on Therapeutic Patents, 2012
- Lasofoxifene in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2010
- Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid ReceptorEndocrinology, 2008
- Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosisExpert Opinion on Investigational Drugs, 2006
- Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I.2005
- Pharmacological Actions of Cannabinoids2005
- Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptorBiochemical Pharmacology, 2003
- Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical PracticeNew England Journal of Medicine, 2003
- Molecular characterization of a peripheral receptor for cannabinoidsNature, 1993